JP2023529065A5 - - Google Patents

Info

Publication number
JP2023529065A5
JP2023529065A5 JP2022568723A JP2022568723A JP2023529065A5 JP 2023529065 A5 JP2023529065 A5 JP 2023529065A5 JP 2022568723 A JP2022568723 A JP 2022568723A JP 2022568723 A JP2022568723 A JP 2022568723A JP 2023529065 A5 JP2023529065 A5 JP 2023529065A5
Authority
JP
Japan
Prior art keywords
composition according
nanoparticles
hpv
immunogenic fragment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529065A (ja
Filing date
Publication date
Priority claimed from EP20174156.8A external-priority patent/EP3909612A1/en
Application filed filed Critical
Publication of JP2023529065A publication Critical patent/JP2023529065A/ja
Publication of JP2023529065A5 publication Critical patent/JP2023529065A5/ja
Pending legal-status Critical Current

Links

JP2022568723A 2020-05-12 2021-05-12 Ｈｐｖ由来の免疫原性フラグメントのためのの担体としてのナノ粒子の組成物 Pending JP2023529065A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20174156.8A EP3909612A1 (en) 2020-05-12 2020-05-12 Composition of nanoparticles
EP20174156.8 2020-05-12
EP20196027.5 2020-09-14
EP20196027.5A EP3909614A1 (en) 2020-05-12 2020-09-14 Composition of nanoparticles as carrier for hpv-derived immunogenic fragments
PCT/EP2021/062748 WO2021229014A1 (en) 2020-05-12 2021-05-12 Composition of nanoparticles as carrier for hpv-derived immunogenic fragments

Publications (2)

Publication Number Publication Date
JP2023529065A JP2023529065A (ja) 2023-07-07
JP2023529065A5 true JP2023529065A5 (enExample) 2024-05-22

Family

ID=70682623

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022568554A Pending JP2023524874A (ja) 2020-05-12 2021-05-12 ナノ粒子の組成物
JP2022568723A Pending JP2023529065A (ja) 2020-05-12 2021-05-12 Ｈｐｖ由来の免疫原性フラグメントのためのの担体としてのナノ粒子の組成物
JP2022568724A Pending JP2023529066A (ja) 2020-05-12 2021-05-12 アジュバント／抗原の担体系としてのナノ粒子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022568554A Pending JP2023524874A (ja) 2020-05-12 2021-05-12 ナノ粒子の組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022568724A Pending JP2023529066A (ja) 2020-05-12 2021-05-12 アジュバント／抗原の担体系としてのナノ粒子

Country Status (4)

Country Link
US (4) US20230272014A1 (enExample)
EP (6) EP3909612A1 (enExample)
JP (3) JP2023524874A (enExample)
WO (3) WO2021229020A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3909612A1 (en) * 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
CN113274492B (zh) * 2021-05-21 2022-06-17 大连理工大学 一种基于羟基氧化铝纳米羧基改性的复合疫苗佐剂的制备方法
US20240042070A1 (en) * 2022-06-28 2024-02-08 Transcode Therapeutics, Inc. Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy
EP4673166A1 (en) * 2023-03-02 2026-01-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Therapeutic hpv vaccines based on validated target epitopes
WO2024180234A1 (en) * 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Validated hpv16-derived stimulation peptides
WO2024180233A1 (en) * 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts A therapeutic hpv vaccine based on validated target epitopes

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3616133A1 (de) 1985-09-25 1987-11-19 Merck Patent Gmbh Kugelfoermige sio(pfeil abwaerts)2(pfeil abwaerts)-partikel
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
DE69425356T2 (de) 1993-09-22 2002-04-18 Hoechst Ag Pro-Prodrugs, ihre Herstellung und Anwendung
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
DE19912502A1 (de) * 1999-03-19 2000-09-21 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung
NZ517928A (en) 1999-09-27 2004-09-24 Coley Pharm Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
DE102004011110A1 (de) 2004-03-08 2005-09-22 Merck Patent Gmbh Verfahren zur Herstellung monodisperser SiO2-Partikel
WO2006017476A2 (en) * 2004-08-02 2006-02-16 The Research Foundation Of State University Of New York Amino functionalized ormosil nanoparticles as delivery vehicles
WO2006037979A2 (en) 2004-10-01 2006-04-13 Midatech Limited Nanoparticles comprising antigens and adjuvants and immunogenic structure
JP4981681B2 (ja) 2004-12-09 2012-07-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法
WO2006070376A1 (en) * 2004-12-30 2006-07-06 Hadasit Medical Research Services & Development Ltd. Antimicrobial nanoparticulate additives forming non-leachable sustained antimicrobial polymeric compositions
EP1764107A1 (en) 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
AU2006290567A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A Comb polymers
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
FR2908305B1 (fr) 2006-11-10 2009-02-27 Oreal Procede de deformation permanente des fibres keratiniques comprenant une etape d'application d'une composition de rincage intermediaire comprenant un sel de cation metallique monovalent ou un sel d'ammonium et un acide organique
JP5448369B2 (ja) * 2008-05-15 2014-03-19 古河電気工業株式会社 粒子表面にアミノ基を有するシリカ粒子の製造方法、粒子表面にアミノ基を有するシリカ粒子、及びそれを用いた複合粒子
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
EP4015636B1 (en) 2008-05-21 2024-11-20 Rheinische Friedrich-Wilhelms-Universität Bonn 5' triphosphate oligonucleotide with blunt end and uses thereof
DE102008033175A1 (de) 2008-07-15 2010-01-21 Merck Patent Gmbh Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
AU2010225129A1 (en) 2009-03-17 2010-09-23 Gunther Hartmann TLR7 ligand and uses thereof
ES2366841B1 (es) * 2010-04-06 2013-01-24 Consejo Superior De Investigaciones Cientificas (Csic) (45%) Nanoparticulas de silice para difusion intracelular de agentes bioactivos poco solubles
AU2011263546B2 (en) 2010-06-10 2015-01-22 Midatech Limited Peptide-carrying nanoparticles
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
AU2012306243B2 (en) 2011-09-07 2016-10-20 Midatech Limited Nanoparticle-peptide compositions
MX2014002764A (es) 2011-09-07 2014-12-04 Midatech Ltd Vacunas en nanoparticulas para tumor.
EP2883550A1 (en) 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
EP3134124B1 (en) 2014-04-25 2019-02-20 Pierre Fabre Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
US11786469B2 (en) * 2014-07-22 2023-10-17 Cheolhee WON Silica nanoparticle composition for delivering bioactive material or protein such as a human proteasome
WO2016054225A1 (en) * 2014-09-30 2016-04-07 Stc.Unm Plasmid delivery in the treatment of cancer and other disease states
EP3370741B1 (en) * 2015-11-04 2025-10-08 The Trustees of the University of Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
KR102317281B1 (ko) * 2015-11-17 2021-10-25 하이라이트 테라퓨틱스 에스.엘. 이본쇄 폴리리보뉴클레오타이드 및 폴리알킬렌이민의 복합체를 포함하는 입자를 포함하는 신규 약제학적 조성물
WO2017223085A2 (en) * 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2018085751A1 (en) 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
US20200375912A1 (en) * 2017-08-03 2020-12-03 Rita Elena Serda Liposomal coated nanoparticles for immunotherapy applications
GB201718817D0 (en) * 2017-11-14 2017-12-27 N4 Pharma Uk Ltd Particulate material production process
US20210196838A1 (en) * 2018-08-24 2021-07-01 Mirexus Biotechnologies Inc. Compounds and compositions for potentiation of tlr agonists
EP3909612A1 (en) * 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles

Similar Documents

Publication Publication Date Title
JP2023529066A5 (enExample)
CN114366809B (zh) 一种铝纳米晶递送系统及其结合疫苗抗原分子自组装颗粒佐剂疫苗
CN103372217B (zh) 聚合物纳米载体制剂及其制备方法和应用
JP2023524874A5 (enExample)
CN108078958B (zh) 一种抗肿瘤多肽纳米药物及其制备方法和应用
CN103690961B (zh) 一种智能两亲性聚合物纳米胶束及其制备方法和应用
JP2019537424A5 (enExample)
JP2012532185A5 (enExample)
CN106008716B (zh) 呼吸道合胞病毒抗原组合物和方法
CN111658780A (zh) 一种基于阴离子聚合物及其衍生物制备的疫苗载体
ES2246695A1 (es) Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
Dong et al. A visible fluorescent nanovaccine based on functional genipin crosslinked ovalbumin protein nanoparticles
JP2016510813A (ja) ワクチン接種用組成物
CN110139826A (zh) 具有负的表面电荷的微粒和纳米颗粒
US20230310621A1 (en) Complexes for the delivery of proteinaceous agents
JP2023529839A5 (enExample)
JP2023529066A (ja) アジュバント／抗原の担体系としてのナノ粒子
CN102397266A (zh) 纳米颗粒的制备方法及用该方法制备的纳米颗粒
CN115501322A (zh) 用于肿瘤免疫治疗的多肽药物偶联物、载药系统、药物组合系统及应用
CN114615986B (zh) 具备cGAS-STING通路激活功能的纳米颗粒及其制备方法和应用
Zhao et al. Melanoma immunotherapy enabled by M2 macrophage targeted immunomodulatory cowpea mosaic virus
JP2004521911A (ja) 投薬方式
Hasnain et al. Carbon nanotubes in vaccine delivery
CN110694057A (zh) 一种可控捕获/释放抗原的纳米复合胶束癌症疫苗的制备方法
JP2020530453A5 (enExample)